0001104659-20-071839.txt : 20200610
0001104659-20-071839.hdr.sgml : 20200610
20200610112203
ACCESSION NUMBER: 0001104659-20-071839
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200610
FILED AS OF DATE: 20200610
DATE AS OF CHANGE: 20200610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sard Mark
CENTRAL INDEX KEY: 0001737651
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35619
FILM NUMBER: 20954033
MAIL ADDRESS:
STREET 1: STEMLINE THERAPEUTICS, INC.
STREET 2: 750 LEXINGTON AVENUE, 11TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: STEMLINE THERAPEUTICS INC
CENTRAL INDEX KEY: 0001264587
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 450522567
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 750 LEXINGTON AVENUE
STREET 2: ELEVENTH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: 646-502-2311
MAIL ADDRESS:
STREET 1: 750 LEXINGTON AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10022
4
1
a4.xml
4
X0306
4
2020-06-10
1
0001264587
STEMLINE THERAPEUTICS INC
STML
0001737651
Sard Mark
C/O STEMLINE THERAPEUTICS, INC.
750 LEXINGTON AVENUE, ELEVENTH FLOOR
NEW YORK
NY
10022
1
0
0
0
Common Stock
2020-06-10
4
U
0
51468
D
0
D
Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020, in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021.
/s/ Kenneth Hoberman, Attorney-in-Fact
2020-06-10